KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Amortization - Intangibles (2017 - 2024)

BeOne Medicines (ONC) has disclosed Amortization - Intangibles for 8 consecutive years, with $1.2 million as the latest value for Q1 2024.

  • On a quarterly basis, Amortization - Intangibles rose 19.98% to $1.2 million in Q1 2024 year-over-year; TTM through Jun 2024 was $8.0 million, a 68.28% increase, with the full-year FY2023 number at $7.2 million, up 82.07% from a year prior.
  • Amortization - Intangibles was $1.2 million for Q1 2024 at BeOne Medicines, down from $3.0 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $3.9 million in Q3 2023 to a low of $187000.0 in Q3 2020.
  • A 5-year average of $995941.2 and a median of $404000.0 in 2021 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: plummeted 53.71% in 2022, then skyrocketed 1989.3% in 2023.
  • BeOne Medicines' Amortization - Intangibles stood at $188000.0 in 2020, then surged by 512.77% to $1.2 million in 2021, then surged by 124.05% to $2.6 million in 2022, then increased by 14.57% to $3.0 million in 2023, then crashed by 59.99% to $1.2 million in 2024.
  • Per Business Quant, the three most recent readings for ONC's Amortization - Intangibles are $1.2 million (Q1 2024), $3.0 million (Q4 2023), and $3.9 million (Q3 2023).